Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

[1]  K. Kern,et al.  Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Greil,et al.  Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Schneeweiss,et al.  No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study. , 2009 .

[4]  J. Blay,et al.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.

[5]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[6]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[8]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[9]  O. Nanni,et al.  Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. van Marck,et al.  Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia , 2004, British Journal of Cancer.

[11]  G. Sledge,et al.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.

[12]  B Landuyt,et al.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 , 2003, British Journal of Cancer.

[13]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Sargent,et al.  A three-outcome design for phase II clinical trials. , 2001, Controlled clinical trials.

[15]  J. Klijn,et al.  Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Pavlidis,et al.  Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. , 1997, European journal of cancer.

[18]  A. Amodio,et al.  Paclitaxel Activity in Anthracycline Refractory Breast Cancer Patients , 1997, Tumori.

[19]  N. Davidson.  Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. , 1996, Seminars in oncology.

[20]  P M Ravdin,et al.  Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Hudis,et al.  Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Caraceni,et al.  Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. , 1995, Journal of the National Cancer Institute.